Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/thoraxjnl-2020-216243 http://scihub22266oqcxt.onion/10.1136/thoraxjnl-2020-216243 33408195!ä!33408195 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Thorax 2021 ; 76 (4): 412-420 Nephropedia Template TP {{tp|p=33408195|t=2021. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms |pdf=|usr=}}{{33408195}} gab.com Text COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms JO: Thorax http://www.kidney.de/pget.php?&tw=1&pmid=33408195 #FOAvip Thrombotic events that frequently occur in COVID-19 are predominantly venous thromboemboli (VTE) and are associated with increasing disease severity and worse clinical outcomes. Distinctive microvascular abnormalities in COVID-19 include endothelial inflammation, disruption of intercellular junctions and microthrombi formation. A distinct COVID-19-associated coagulopathy along with increased cytokines and activation of platelets, endothelium and complement occur in COVID-19, which is more frequent with worsening disease severity. This proinflammatory milieu may result in immunothrombosis, a host defence mechanism that can become dysregulated, leading to excess formation of immunologically mediated thrombi which predominantly affect the microvasculature. The haemostatic and immune systems are intricately linked, and multifactorial processes are likely to contribute to VTE and immunothrombosis in COVID-19. This state-of-the-art review will explore the pathobiological mechanisms of immunothrombosis and VTE in COVID-19 focusing on: COVID-19-associated coagulopathy, pathology, endothelial dysfunction and haemostasis, the immune system and thrombosis, genetic associations and additional thrombotic mechanisms. An understanding of the complex interplay between these processes is necessary for developing and assessing how new treatments affect VTE and immunothrombosis in COVID-19. Twit Text FOAVip COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms ????Thorax http://www.kidney.de/pget.php?&tw=1&pmid=33408195 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33408195 #FOAvip English Wikipedia <ref>{{Cite pmid|33408195}}</ref> COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms #MMPMID33408195 Loo J; Spittle DA; Newnham M Thorax 2021[Apr]; 76 (4): 412-420 PMID33408195show ga Thrombotic events that frequently occur in COVID-19 are predominantly venous thromboemboli (VTE) and are associated with increasing disease severity and worse clinical outcomes. Distinctive microvascular abnormalities in COVID-19 include endothelial inflammation, disruption of intercellular junctions and microthrombi formation. A distinct COVID-19-associated coagulopathy along with increased cytokines and activation of platelets, endothelium and complement occur in COVID-19, which is more frequent with worsening disease severity. This proinflammatory milieu may result in immunothrombosis, a host defence mechanism that can become dysregulated, leading to excess formation of immunologically mediated thrombi which predominantly affect the microvasculature. The haemostatic and immune systems are intricately linked, and multifactorial processes are likely to contribute to VTE and immunothrombosis in COVID-19. This state-of-the-art review will explore the pathobiological mechanisms of immunothrombosis and VTE in COVID-19 focusing on: COVID-19-associated coagulopathy, pathology, endothelial dysfunction and haemostasis, the immune system and thrombosis, genetic associations and additional thrombotic mechanisms. An understanding of the complex interplay between these processes is necessary for developing and assessing how new treatments affect VTE and immunothrombosis in COVID-19. |*Pandemics[MESH] |*SARS-CoV-2[MESH] |COVID-19/blood/*complications/epidemiology[MESH] |Cytokines/*blood[MESH] |Global Health[MESH] |Humans[MESH] |Incidence[MESH]COVID-19, immunothrombosis and venous thromboembolism: biological mech(epmc).pdf DeepDyve Pubget Overpricing